Abstract
BackgroundPembrolizumab was recently demonstrated to have survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma (r/mHNSCC). However, the cost-effectiveness of pembrolizumab versus chemotherapy in China...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have